

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>REVA Medical, Inc.</b>
<b>ARBN</b>	<b>146 505 777</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr. Ross A. Breckenridge
<b>Date of last notice</b>	31 May 2016

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	21 July 2016
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>• 10,000 CDIs (equivalent to 1,000 shares of common stock)</li> <li>• 15,000 shares of common stock (equivalent to 150,000 CDIs)</li> <li>• 30,000 options, each to acquire 1 share of common stock at an exercise price of US\$3.90 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> <li>• 11,800 options each to acquire 1 share of common stock at an exercise price of US\$8.30 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> <li>• 6,300 restricted stock units, each for 1 share of common stock upon vesting, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> </ul>
<b>Class</b>	<ul style="list-style-type: none"> <li>• CDIs (10,000 CDIs)</li> <li>• Common stock (15,000 shares of common stock)(equivalent to 150,000 CDIs)</li> <li>• Options (over 41,800 shares) (equivalent to 418,000 CDIs)</li> <li>• Restricted stock units (over 6,300 shares ) (equivalent to 63,000 CDIs)</li> </ul>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	17,730 CDIs (equivalent to 1,773 shares of common stock)
<b>Number disposed</b>	None
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	A\$17,375.40
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>• 27,730 CDIs (equivalent to 2,773 shares of common stock)</li> <li>• 15,000 shares of common stock (equivalent to 150,000 CDIs)</li> <li>• 30,000 options, each to acquire 1 share of common stock at an exercise price of US\$3.90 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> <li>• 11,800 options each to acquire 1 share of common stock at an exercise price of US\$8.30 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> <li>• 6,300 restricted stock units, each for 1 share of common stock upon vesting, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Off-market purchase of CHES Depository Interests ("CDIs")

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	Yes
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Yes
<b>If prior written clearance was provided, on what date was this provided?</b>	July 7, 2016 (US time)

+ See chapter 19 for defined terms.

For personal use only